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Abstract 
The repertoire of peptides displayed at the cell surface by major histocompatibility complex 
class I (MHC I) molecules is shaped by two intracellular peptide editors, tapasin and 
TAPBPR. While cell-free assays have proven extremely useful in identifying the function of 
both these proteins, here we explored whether a more physiological system could be 
developed to assess TAPBPR-mediated peptide editing on MHC I.  We reveal that 
membrane-associated TAPBPR targeted to the plasma membrane retains its ability to 
function as a peptide editor and efficiently catalyses peptide exchange on surface expressed 
MHC I molecules.  Additionally, we show that soluble TAPBPR, consisting of the lumenal 
domain alone, added to intact cells, also functions as an effective peptide editor on surface 
MHC I molecules.  Thus, we have established two novel systems in which TAPBPR-
mediated peptide exchange on MHC class I can be interrogated. Furthermore, we could use 
both plasma membrane-targeted and exogenous soluble TAPBPR to display immunogenic 
peptides on surface MHC I molecules and consequently induce T cell receptor engagement, 
IFNγ secretion, and T cell-mediated killing of target cells. Thus, we have developed a novel 
and efficient way to by-pass the natural antigen presentation pathway of cells and load 
immunogenic peptides of choice onto cells. Our findings highlight a potential therapeutic use 
for TAPBPR in increasing the immunogenicity of tumours in the future. 
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Significant statement 
MHC class I molecules present small fragments of proteins from within the cell to alert the 
immune system to infection and cellular damage. Two protein accessory proteins, tapasin and 
TAPBPR, assist in the loading and selection of these peptides inside the cell. Here we show 
that one of these proteins, TAPBPR, surprisingly still works when delivered to the outside of 
cells and can be used to load peptides from viruses and tumours directly on surface MHC 
molecules.  Therefore, we have found an efficient way to override the peptides naturally 
presented by cells and can use this to target immune responses against cells. This may prove 
beneficial to mount immune responses against cancer in the future.  
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\body 
Optimal peptide selection on MHC I molecules is essential to mount effective anti-viral and 
anti-tumour immune responses. This process is aided by two intracellular MHC I peptide 
editors. The first peptide editor identified was tapasin, which works within the peptide-
loading complex (PLC), which is where peptides are imported into the endoplasmic reticulum 
(1-4). Following our initial identification of a role for TAPBPR in the MHC I antigen 
processing and presentation pathway (5), TAPBPR was more recently shown to function as a 
second peptide editor for MHC I molecules (6, 7). Molecular insight regarding the 
mechanisms by which peptide editors can help assist in the selection of high-affinity peptides 
onto MHC I has recently been provided with the determination of two crystal structures of 
human TAPBPR in complex with mouse MHC I molecules (8, 9).  In contrast to tapasin, 
TAPBPR is not a component of the PLC (5), however it can recruit UDP-
glucose:glycoprotein glucosyltransferase 1 to provide a quality control checkpoint in the 
process of peptide selection on MHC I (10). Thus, the two MHC I peptide editors work in 
different environments to shape the peptide repertoire presented to the immune system.  
 
In 2007, two elegant assays were developed in order to directly explore the ability of tapasin 
to mediated peptide exchange on MHC class I; one involved artificially zippering tapasin to 
MHC I and measuring peptide exchange using fluorescent anisotropy in vitro (11), whereas 
the other used a recombinant tapasin-ERp57 disulphide-linked conjugate and measured its 
effect on peptide exchange, using iodinated peptides in a cell-free system (12). We, and 
others, previously used an approach analogous to the one developed by Chen and Bouvier 
(11) to demonstrate that TAPBPR enabled efficient peptide exchange on MHC I in vitro; 
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however, as opposed to tapasin, the lumenal domain of TAPBPR alone, in the absence of an 
artificial intermolecular tether, was sufficient to mediate exchange in this system (6, 7). 
As TAPBPR normally performs peptide editing on glycosylated MHC I molecules within a 
cellular environment, we wondered whether a more physiological system could be developed 
to explore TAPBPR-mediated peptide exchange. Although TAPBPR usually resides 
intracellularly, we previously observed that over-expression of TAPBPR results in a 
proportion of TAPBPR mis-localising to the cell surface (5). We speculated that this surface 
pool of TAPBPR still interacts with MHC I and could thus function as a peptide editor on the 
plasma membrane. Here, we explore the ability of both plasma membrane-targeted and 
exogenous soluble TAPBPR to function as peptide exchange catalysts on surface expressed 
MHC I molecules.  We reveal that both forms of TAPBPR function as efficient peptide-
exchange catalysts on surface expressed MHC class I molecules and can be utilised to display 
immunogenic peptides at the surface of various tumour cell lines to CD8+ cytotoxic T 
lymphocytes (CTL).  
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Results 
Plasma membrane expressed TAPBPR promotes exogenous peptide association onto 
surface MHC I 
While IFNγ-treated HeLaM and HeLaM-TAPBPRKO cells do not express TAPBPR on their 
cell surface, the transduction of TAPBPRWT into HeLaM-TAPBPRKO results in significant 
expression of TAPBPR at the plasma membrane (Fig. 1a). The functionality of surface 
expressed TAPBPR was unknown. To explore whether the pool of surface expressed 
TAPBPR retains its peptide editing functionality, we first asked whether a fluorescently-
labelled exogenous peptide specific for HLA-A*68:02 (an MHC class I molecule expressed 
by HeLaM cells) exhibited increased binding to cells expressing surface TAPBPR compared 
to cells lacking surface TAPBPR. Upon incubation with a fluorescent variant of the 
neoantigen ETVSEQSNV, which binds to HLA-A*68:02 with high affinity (13), cells 
expressing TAPBPRWT became fluorescent, while cells that lacked surface TAPBPR 
remained non-fluorescent (Fig. 1b).  We next investigated the binding of two additional 
fluorescent peptides: YVVPFVAK*V, which binds to HLA-A*68:02; and EGVSK*QSNG, a 
non-binding derivative of ETVSK*QSNV, in which the anchor residues that permit HLA-
A*68:02 binding are mutated. While YVVPFVAK*V significantly bound to cells expressing 
TAPBPRWT, but not to HeLaM-TAPBPRKO cells, EGVSK*QSNG did not bind to either cell 
line (Fig. S1a & Fig. 1c). These data suggest that the cellular fluorescence observed was due 
to peptide binding to MHC I, rather than via peptide internalisation. Furthermore, when cells 
expressing surface TAPBPR were incubated at 4oC to inhibit membrane trafficking (Fig. S2a 
&2b), a significant amount of exogenous peptide still bound within 5 minutes providing 
additional evidence that peptide binding occurs directly at the plasma membrane.  
To provide further evidence that the surface pool of TAPBPR, rather than its over-expression, 
was responsible for loading exogenous peptide onto surface MHC I, we generated two 
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chimeric TAPBPR constructs that target TAPBPR to different subcellular sites. Plasma 
membrane (PM) targeting of the lumenal portion of TAPBPR was achieved by replacing the 
cytoplasmic tail of TAPBPR with that of CD8 (TAPBPRPM)(14), while TAPBPR was 
retained within the ER by replacing its transmembrane domain and cytoplasmic tail with 
those of tapasin (TAPBPRER) (2, 3).  In contrast to TAPBPRPM, which was expressed at high 
levels on the cell surface, TAPBPRER was not found on the plasma membrane (Fig. 1d). Only 
cells expressing TAPBPRPM were able to bind to exogenous fluorescent peptides specific for 
HLA-A*68:02 molecules, YVVPFVAK*V and ETVSK*QSNV (Fig. 1c, 1e & Fig. S1b).  
No significant fluorescent peptide binding was detectable on cells expressing TAPBPRER 
(Fig. 1c, 1e & Fig. S1b).  These results suggest that surface TAPBPR promotes the loading 
of exogenous peptide onto surface expressed MHC I. 
 
Plasma membrane expressed TAPBPR associates with surface MHC I  
Given the results above, we next confirmed that cell surface expressed TAPBPR physically 
associated with surface MHC I.   Immunoprecipitation of the surface pool of TAPBPR from 
both TAPBPRWT and TAPBPRPM expressing cells confirmed it was associated with MHC I, 
but not with UGT1 (Fig. 1f). As expected, negligible levels of TAPBPRER were detectable 
using this technique, verifying the lack of significant cross-contamination of intracellular 
TAPBPR in the cell surface immunoprecipitates (Fig. 1f).  Isolation of the intracellular 
TAPBPR pool, confirmed all TAPBPR variants were expressed and associated with 
intracellular MHC I (Fig. 1f). In contrast to TAPBPRPM, we observed that UGT1 associates 
with both TAPBPRWT and TAPBPRER, supporting the predicted subcellular localisation of 
the chimeric proteins (Fig. 1f). Taken together, these results suggest that surface localisation 
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of TAPBPR, rather than its intracellular over-expression, is responsible for the loading of 
exogenous peptide onto MHC I at the plasma membrane. 
 
Surface expressed tapasin does not promote substantial exogenous peptide association 
onto surface MHC I 
As tapasin is also an MHC I peptide editor, we next asked whether tapasin could similarly 
load exogenous peptide onto MHC I when expressed at the cell surface. The overexpression 
of tapasinWT did not result in tapasin expression at the cell surface (Fig. 1g), most probably 
due to the ER retention motif found in its cytoplasmic tail (2, 3). We, therefore, replaced the 
cytoplasmic tail of tapasin with that of CD8 (tapasinPM) which led to tapasin expression at the 
cell surface (Fig. 1g). When the ability of cells expressing surface tapasin to bind to 
exogenous fluorescent peptides was tested, there was a significant, but very slight increase in 
peptide binding of both ETVSK*QSNV (Fig. 1h & 1i) and YVVPFVAK*V (Fig. 1i & Fig. 
S1c). Our results suggest that TAPBPRPM is at least 10-fold more efficient at promoting 
peptide binding in this situation, compared with tapasinPM. This finding is consistent with the 
differences observed in the ability of TAPBPR and tapasin to facilitate peptide exchange 
using other reported assays, in which TAPBPR alone functions as an efficient peptide editor 
without the need for zippering to MHC I (6, 7). In contrast, tapasin requires other association 
partners or artificial zippering to MHC I (11, 12). We speculate that this low level of peptide 
binding observed to cells expressing surface tapasin is due the export of peptide-receptive 
MHC I with tapasin to the cell surface, rather than the surface tapasin efficiently facilitating 
peptide exchange.  
 
TAPBPR mediates exogenous peptide binding quickly and at low peptide concentration  
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When we explored the kinetics of TAPBPR-mediated peptide binding to cells over time, we 
observed a striking increase in both the magnitude and speed at which this occurred (Fig. 2a 
& Fig. S2c). Within 5 minutes we observed a >200-fold increase in the level of exogenous 
peptide binding in cells expressing surface TAPBPR compared with the HeLaM and HeLaM-
TAPBPRKO controls (Fig. 2a). Furthermore, TAPBPR-mediated peptide binding occurred at 
extremely low concentrations of peptide compared to cells lacking surface TAPBPR 
expression (Fig. 2b & Fig. S2d). TAPBPR-mediated peptide binding required approximately 
100-fold less peptide to obtain equivalent peptide binding, compared to cells lacking surface 
TAPBPR expression (Fig. 2b).   These findings demonstrate that surface TAPBPR mediates 
peptide association onto surface MHC I molecules extremely rapidly and at very low 
concentrations of peptide.  
 
Surface TAPBPR functions as a peptide exchange catalyst on surface MHC I 
There are two conceivable mechanisms by which surface expressed TAPBPR could promote 
the loading of exogenous peptides onto MHC class I; it may drag peptide-receptive MHC 
class I molecules with it through the secretory pathway to the cell surface and/or it may retain 
its ability to function as a peptide exchange catalyst in this atypical location. Given that 
enhanced peptide binding continued over a prolonged period on cells expressing surface 
TAPBPR (Fig. 2a), it was probable that TAPBPR retained its ability to function peptide 
exchange catalyst at this atypical location.  To explore this, we developed an assay to directly 
assess whether TAPBPR actively mediated peptide dissociation from MHC I at the cell 
surface (Fig. 2c). First, cells expressing surface TAPBPR were incubated with fluorescently-
labelled peptide for 15 minutes to enable surface HLA-A*68:02 molecules to bind to labelled 
peptides. Subsequently, cells were extensively washed to remove any unbound peptide, thus 
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removing any excess fluorescent peptide from the system. We then tested the ability of cells 
to dissociate the labelled peptide in the presence of a vast excess of unlabelled competitor 
peptides. Using this method, we observed dissociation of both YVVPKVAK*V (Fig. 2d) and 
ETVSK*QSNV (Fig. 2e) in the presence of a high affinity unlabelled competitor peptide 
(ETVSEQSNV or YVVPFVAKV), but not in the presence of a non-binding competitor 
peptide (EGVSEQSNG). This suggests that surface TAPBPR is capable of promoting peptide 
exchange from MHC I molecules in a peptide-affinity (YVVPFVAKV> 
ETVSEQSNV>EGVSEQSNQ) and peptide-concentration dependent manner (Fig. 2f & 2g).  
In keeping with this, the binding of YVVPFVAK*V to cells expressing surface TAPBPR 
appeared as a single sharp peak (e.g. Fig. S1a, Fig. 2d), while the binding of ETVSK*QSNV 
appeared bimodal in comparison (e.g. Fig. 1b, Fig. 2e).  Although in our standard assay 
conditions (10 nM peptide for 15 min at 37oC) ETVSK*QSNV was not at saturation, the 
binding of this peptide to cells expressing surface TAPBPR was improved by either 
increasing the time of peptide incubation (Fig. S2c) or by increasing the concentration of 
peptide used (Fig. S2d). The binding of ETVSK*QSNV could be brought up to comparable 
levels and distribution as observed with 10 nM YVVPFVAK*V by increasing 
ETVSK*QSNV concentration to 1µM (Fig. S2d). Thus, the differences observed in the 
pattern of peptide binding to cells appears to be due to the different affinity of the two 
peptides for HLA-A*68:02 (YVVPFVAK*V> ETVSK*QSNV), rather than heterogeneity of 
the cells.  
Surprisingly, TAPBPR also retained this catalytic activity at 4oC, albeit at a slower rate and 
in the presence of a higher concentration of competitor peptide (Fig. S3a & Fig. S3b). To 
rule out the possibility that peptide was simply binding to empty MHC I expressed on the 
surface, cells incubated at 4oC to inhibit further membrane trafficking and a reversed assay to 
measure peptide exchange was performed. Cells at 4oC were first incubated with an excess of 
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unlabelled high affinity peptide to occupy any potentially empty MHC I molecules with 
peptide. Then, after extensive washing to remove any excess unbound peptide, cells were 
subsequently incubated with a fluorescent competitor peptide (Fig. S3c). We still observed 
high levels of fluorescent peptide binding to cells in the presence of surface TAPBPR, but not 
in its absence (Fig. S3d). Thus, for TAPBPR to promote fluorescent peptide loading observed 
in this assay, it must have dissociated peptide from MHC I first.  
Taken together, although these findings do not exclude the possibility that surface TAPBPR 
carries some peptide-receptive MHC I molecules en route, they do demonstrate that TAPBPR 
retains its ability to function as a peptide exchange catalyst when expressed on the cell 
surface. Thus, membrane-bound TAPBPR expressed on the surface of a cell can be used as a 
novel assay to interrogate TAPBPR-mediated peptide exchange on MHC I on a cellular 
membrane.  
 
Soluble TAPBPR facilitates peptide exchange on surface HLA-A*68:02 molecules 
Following on from this, we were curious whether soluble exogenous TAPBPR added to cells 
was also capable of functioning as a peptide exchange catalyst on surface MHC I molecules. 
First, we tested whether soluble TAPBPR, consisting only of its lumenal domain (i.e lacking 
its transmembrane domain and cytoplasmic tail) could bind to surface MHC I molecules. 
When we incubated HeLaM cells with soluble TAPBPRWT for 15 minutes, TAPBPR was 
clearly detectable on the cell surface (Fig. 3a). The binding of TAPBPR to cells was 
dependent on its association with MHC I since soluble TAPBPRTN5, a mutant that cannot 
bind to MHC I (15), did not bind to HeLaM cells (Fig. 3a) and since soluble TAPBPRWT 
could no longer bind to HeLaM cells in which HLA-ABC had been knocked out (Fig. 3a). 
Furthermore, the binding of soluble TAPBPRWT to HLA-ABC deficient HeLaM cells was 
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restored when HLA-A*68:02 expression was reconstituted (Fig. S4a). In addition, soluble 
TAPBPRWT, but not TAPBPRTN5, bound to MHC I in TAPBPR pulldown experiments (Fig. 
3b). 
Next, we explored the capability of soluble TAPBPR to promote peptide exchange on surface 
MHC I molecules by testing its ability to replace the naturally-presented peptide, with an 
exogenously-added fluorescent peptide.  Cells were pre-treated -/+ soluble TAPBPR for 15 
min, followed by incubation -/+ fluorescent peptide with varying affinity for HLA-A*68:02 
for an additional 15 min (Fig. 3c).  Subsequently, the amount of fluorescent peptide bound to 
cells was determined using flow cytometry. We found soluble TAPBPRWT significantly 
enhanced the association of fluorescent peptides specific for HLA-A*68:02, ETVSK*QSNV 
and YVVPKVAK*V, onto HeLaM cells (Fig. 3d & 3e). Negligible peptide binding was 
observed either in the absence of soluble TAPBPRWT or in the presence of soluble 
TAPBPRTN5 (Fig. 3d & 3e). No association was observed for the non-binding peptide, 
EGVSK*QSNG, under any of the conditions tested (Fig. 3e, Fig. S4b & Fig. S4c). 
Strikingly, soluble TAPBPRWT promoted peptide association onto cells at extremely low 
levels of exogenous peptide, requiring approximately 1000-fold less peptide to obtain the 
equivalent peptide binding observed in the absence of TAPBPR (Fig. 3f). Exogenous peptide 
binding to cells via soluble TAPBPRWT occurred directly onto MHC I since peptide 
association was only observed on MHC I competent cells and not on MHC I deficient 
counterparts (Fig. 3f & Fig. S4b) and binding was restored upon HLA-A*68:02 
reconstitution (Fig. S4c & S4d). Furthermore, soluble TAPBPRTN5, which cannot bind to 
MHC I, was incapable of promoting peptide association (Fig. 3f). These results clearly 
demonstrate that the lumenal domain of TAPBPR alone is sufficient to promote peptide 
exchange on surface HLA-A*68:02 molecules.  Thus, by incubating intact cells with soluble 
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TAPBPR, we now have a second novel assay on a cellular membrane to explore TAPBPR-
mediated peptide editing on MHC class I. 
 
Soluble TAPBPR facilitates peptide exchange on surface HLA-A*02:01 molecules 
We extended our analysis to test the ability of soluble TAPBPR to load a range of exogenous 
peptides onto another human MHC I molecule, HLA-A*02:01, expressed on HeLaM-HLA-
ABCK0-A2+ cells. In TAPBPR pulldown experiments, we observed an association between 
soluble TAPBPRWT, but not TAPBPRTN5, with HLA-A2 expressed in HeLaM-HLA-ABCKO-
A2+ cells (Fig. S5a). Soluble TAPBPRWT significantly promoted the binding of fluorescently 
labelled variants of: NLVPMVATV (an immunogenic peptide derived from the CMV protein 
pp65 (16)); YVVPFVAKV (derived from human CCR4-NOT transcription complex subunit 
1(6)); and YLLEMLWRL (an immunogenic peptide derived from the EBV protein Latent 
membrane protein 1(LMP1)(17))(Fig. 3g & Fig. S5b).  The TAPBPR-promoted loading of 
these peptides was dependent on HLA-A2, as fluorescent peptide binding was not detectable 
on HLA-A2 negative cells (Fig. S5c & S5d). Soluble TAPBPRWT did not promote binding of 
peptides specific for other MHC I molecules onto HLA-A2 and also did not significantly 
enhance the association of the HLA-A2 binding peptide CLGGLLTMV, an immunogenic 
peptide derived from the EBV protein Latent membrane protein 2 (Fig. 3g & Fig. S5b).  
Together, these data strongly suggest that soluble TAPBPR can promote the loading of 
exogenous peptide onto surface MHC I in an affinity-based manner.   
 
TAPBPR loads immunogenic peptides onto human tumour cells thereby inducing their 
recognition by T cells  
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Having identified that adding soluble TAPBPR to intact cells is a novel, efficient and 
extremely fast way of overriding the endogenous antigen processing and presentation 
pathway of cells, we were interested in testing whether this may have any translational 
potential. As the ability to increase neoantigen or indeed foreign antigen presentation on 
tumours would prove extremely useful in overcoming low immunogenicity often observed in 
tumours (18), we next tested whether soluble TAPBPR could enhance the binding of both 
tumour-derived and viral peptides onto tumour cells. We found that soluble TAPBPRWT 
significantly enhanced the loading of fluorescent derivatives of the tumour antigens 
IMDQVPFSV (derived from gp100)(19), ELAGIGILTV (from Melan-A/MART-1)(20), 
LLGRNSFEV (derived from p53)(21) and RLLQETELV (from HER-2/neu)(22) (Fig. 4a) 
onto HLA-A*02:01 naturally expressed on MCF-7, a breast cancer cell line.  Soluble 
TAPBPRWT also promoted the association of fluorescently labelled derivatives of the viral 
peptides YLLEMLWRL (from EBV LMP1) and NLVPMVATV (from CMV) onto MCF-7 
(Fig. 4b).  
 
We subsequently determined whether the peptides loaded via TAPBPR were available for T 
cell receptor (TCR) detection. Encouragingly, soluble TAPBPR dissociates from cells upon 
high affinity peptide binding onto surface MHC I molecules (Fig. S6), raising the possibility 
that TAPBPR-loaded peptide:MHC complexes might be fully accessible for TCR detection. 
We found that YLLEMLWRL loaded onto MCF-7 cells by TAPBPR was strongly detected 
by the anti-EBV TCR-like mAb L1, specific for LMP1125-133 presented on HLA-A*02:01 (17) 
(Fig. 4c & 4d). Furthermore, NLVPMVATV loaded onto MCF-7 cells by soluble TAPBPR 
significantly increased the stimulation, measure by IFNγ secretion, of human CD8+ T cells 
specific for pp65495–503 presented on HLA-A2 (16), compared with cells incubated with 
peptide alone or in the presence of soluble TAPBPRTN5 (Fig. 4e). We have further verified 
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these findings using HeLaM-HLA-ABCKO-A2+ (Fig. S7).  These results demonstrate that 
soluble TAPBPR can efficiently load antigenic peptides onto tumour cell lines for recognition 
by CD8+ T cells.  
 
Soluble TAPBPR induces tumour cell killing by CD8+ T lymphocytes 
Although the results above suggest that soluble TAPBPR could potentially be utilised to 
decorate target cells with immunogenic peptides and enhance T cell responses against 
tumours, it was important to determine whether this could result in enhanced killing of 
tumour cells. To investigate this possibility, we assessed killing of murine EL4 tumour cells 
by OT1 T cells in the presence of human TAPBPR and very low concentrations of 
SIINFEKL peptide.  Soluble human TAPBPRWT bound to EL4 cells (Fig. 5a) and 
significantly enhanced the loading of SIINFEKL onto H-2Kb expressed on EL4 (Fig. 5b, 5c 
& 5d).  When we tested the ability of OT1 cytotoxic T cells, which recognise SIINFEKL in 
the context of H-2Kb, to lyse peptide-pulsed EL4 target cells, we observed a significant 
enhancement in killing in the presence of soluble human TAPBPRWT, but not in the presence 
of TAPBPRTN5 (Fig. 5e). These results demonstrate that TAPBPR can be utilised to enhance 
the killing of tumours by peptide-specific CD8+ T lymphocytes.  
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Discussion 
Although TAPBPR usually functions as an intracellular peptide editor on MHC I molecules, 
we demonstrate that when given access to the surface pool of MHC I molecules, either 
through targeting full length TAPBPR to the plasma membrane or by adding soluble 
TAPBPR to cells, TAPBPR retains its function as a peptide exchange catalyst. Thus, we have 
developed two novel cell-based peptide-exchange systems for MHC I, which complement 
those already established (11, 12). Here, we have shown that TAPBPR can mediate peptide 
editing on three distinct MHC I molecules (HLA-A*68:02, HLA-A*02:01 and H-2Kb) 
expressed on the surface of cells. As expected, the efficiency of TAPBPR-mediated peptide 
exchange is dependent on affinity of the incoming peptide for a particular MHC I.   
 
Intriguingly, our work, particularly when using soluble TAPBPR, demonstrates that TAPBPR 
can dissociate peptides which apparently have relatively high affinity for MHC I, given that it 
works on MHC complexes expressed on the surface of cells with an intact antigen 
presentation pathway and thus on molecules that have already undergone the process of 
chaperone-mediated quality control. This raises interesting questions regarding the precise 
criteria by which TAPBPR selects peptides. This ability of TAPBPR to outcompete 
apparently good peptides from MHC I relatively quickly may explain why TAPBPR levels in 
cells are quite low.  
 
Our novel cell-based assays for determining the ability of TAPBPR to catalyse peptide 
exchange on MHC class I molecules offer a number of advantages over the already-
established cell-free assays, representing a more physiological system for exploring this 
concept. First, in contrast to the cell-free systems (6, 7, 11, 12), our assays here assess the 
interaction between TAPBPR and MHC I molecules in their naturally-occurring membrane-
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bound conformations, taking into account the restrictions imposed by a cellular membrane, 
either on both the MHC I molecules and on TAPBPR, or on MHC I alone. Second, as 
opposed to the bacterial refolds used in the Chen & Bouvier assay (11), the MHC I molecules 
present in our system are subjected to the naturally-occurring post-translational modifications 
within the cell, as is also the case in Wearsh & Cresswell’s assay (12); moreover, the MHC I 
molecules here are loaded with a broad spectrum of peptides instead of being refolded around 
single individual ones, creating a less-biased and broader range of ligands for TAPBPR. In 
addition, the cellular assays offer the possibility to screen the ability of TAPBPR to function 
as a peptide exchange catalyst on a broad range of MHC molecules in a highly efficient 
manner, simply by using the MHC I molecules expressed on cells, and without the need to 
make bacterial refolds of individual MHC I.  
 
In contrast to TAPBPR, we found that tapasin was not able to perform its peptide editing 
function on surface expressed MHC I molecules. There are a number of potential reasons to 
explain the difference in the ability of the two peptide editors to function on surface MHC I 
molecules. Firstly, as surface expressed MHC I complexes are loaded with good peptides, 
they may no longer be accessible to tapasin-mediated peptide editing. Secondly, TAPBPR 
appears to have higher affinity for MHC I than tapasin (7), a property that contributed to the 
recent success of crystallising the TAPBPR:MHC I complex (8, 9). Thirdly, the lumenal 
domain of TAPBPR alone is known to efficiently mediate peptide exchange (6, 7), while 
tapasin either needs other co-factors or artificial zippering to MHC I (11, 12). Thus, when 
tapasin is targeted to the plasma membrane, it will lack the other co-factors that it requires to 
work efficiently as a peptide editor. Finally, we have recently shown that TAPBPR interacts 
with MHC I in a glycan-independent manner and appears to have no particular preference for 
the glycan attached (Neerincx & Boyle, manuscript in press, Molecular Immunology). This is 
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in contrast to tapasin, which can only associate efficiently with monoglucosylated MHC I, via 
its interactions with calreticulin. Thus, TAPBPR appears to have the ability to function on a 
wider pool of MHC I molecules with the broader range of N-linked glycan attachments than 
tapasin. This now appears to include MHC I with mature sugar attachments.  
 
To the best of our knowledge, our work here represents the first example of a peptide editor 
facilitating peptide exchange directly onto surface MHC I. Strikingly, TAPBPR mediates 
exogenous peptide binding to surface expressed MHC I molecules at an extremely high rate 
and at very low peptide concentrations. Thus, we have identified a novel and highly efficient 
way of overriding the endogenous antigen processing and presentation pathway of cells.   
 
This discovery has a number of potential future applications. To begin with, soluble TAPBPR 
may prove an extremely useful tool for researchers studying immune responses to viruses and 
tumours. By utilising soluble TAPBPR on cells, investigators will be able to manipulate the 
peptides presented directly onto surface expressed MHC I molecules, replacing endogenous 
cargo with specific peptides of choice, such as those derived from viral proteins to tumour 
antigens.  Currently, peptide-pulsing alone, i.e. without a catalyst, is commonly used to load 
exogenous peptides onto MHC I. However, this requires high concentrations of peptide, 
particularly for human MHC I, over a long time period and is often performed on antigen 
processing deficient cells or on cell incubated at 26oC in order to increase its efficiency. The 
level of peptide loading achieved using soluble TAPBPR on intact cells at 37oC for 15 min is 
vastly superior to that observed when cells are incubated at 26oC (>8 fold higher) or to that 
observed on TAP negative cells (Fig. S8). Thus, the addition of soluble TAPBPR will permit 
efficient peptide loading at low concentrations of peptide on any desired cell line at 37oC 
almost instantaneously, which may have additional benefits when moving from in vitro to in 
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vivo experimentation, given the half-life of 8-10mer peptides is likely to be extremely short. 
Furthermore, by creating peptide-receptive MHC I molecules, TAPBPR may permit the study 
of immune responses to exogenous peptides with lower affinity for MHC, which is more 
difficult when using peptide alone.   
 
Perhaps the most exciting implication of our findings is the translational potential of utilising 
TAPBPR to load immunogenic peptides onto tumour cells in order to target them for 
recognition by CTLs. With the recent advances in cancer immunotherapy, powerful anti-
tumour responses of CTLs can be exploited to eliminate cancer (23, 24). Central to CTL-
mediated tumour cell elimination is the recognition of immunogenic peptides presented on 
MHC I molecules. Neoantigens which arise de novo from tumour-specific mutations are 
considered ideal targets, as they are only expressed on cancer cells and thereby avoid central 
tolerance. However, their presentation on MHC I is likely to be low (25, 26). Therefore, the 
ability to increase the expression of such neoantigens, or indeed to induce foreign antigen 
presentation on tumours, would be a fundamental step forward in overcoming low 
immunogenicity often observed in tumours. Thus, our ability to use TAPBPR to increase the 
immunogenicity of cells may represent a major advance for the future of immunotherapy to 
improve treatment outcomes in patients with tumours resistant to current therapies.  
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Materials and Methods 
Constructs 
The expression of full-length TAPBPRWT in the lentiviral vector pHRSIN-C56W-UbEM, 
which produces the protein of interest under the control of the spleen focus-forming 
virus (SFFV) promoter and the GFP derivative emerald under the control of an ubiquitin 
promoter, has been as previously described (5, 15). Tapasin was amplified from cDNA 
isolated from human foreskin fibroblasts using primers tapasinWT-BamHI-for and tapasinWT-
NotI-rev (See Table S1 for primer sequences), followed by cloning into pHRSIN-C56W-
UbEM.  The chimeric constructs TAPBPRPM and tapasinPM were generated using a two-step 
PCR procedure, where the ectodomain and transmembrane domain of either TAPBPR 
(amplified using primers TAPBPRWT-BamHI-for and TAPBPRPM-rev) or tapasin (amplified 
using primers tapasinWT-BamHI-for and tapasinPM-rev) were fused to the cytoplasmic tail of 
CD8 (amplified with primers TAPBPRPM-for and CD8 tail-NotI-rev, or tapasinPM-for and 
CD8 tail-NotI-rev, respectively). TAPBPRER was produced using a similar procedure, in 
which the ectodomain of TAPBPR (amplified with primers TAPBPRWT-BamHI-for and 
TAPBPRER-rev) was fused to the transmembrane and cytoplasmic domains of tapasin 
(amplified using primers TAPBPRER-for and tapasinWT-NotI-rev). Subsequently, these three 
chimeric inserts were cloned into pHRSIN-C56W-UbEM. The luminal domains of either 
TAPBPRWT or TAPBPRTN5 (6) were also cloned in a PiggyBac transposon vector (using 
primer TAPBPR-soluble-for and TAPBPR-soluble-rev) to produce secreted versions of these 
proteins, containing a His tag at the C-terminus in a mammalian expression system. The full 
length HLA-A*02:01 and HLA-A*68:02 constructs were cloned into the lentiviral vector 
pHRSINcPPT-SGW (15).  HCMV pp65 was cloned into the lentiviral vector pHRSIN-
C56W-UbEM.  
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Cell culture 
HeLaM cells, a variant HeLa cell line that is more responsive to IFN (27) (a gift from Paul 
Lehner, University of Cambridge, UK), their modified variants, HEK-293T cells (from Paul 
Lehner, University of Cambridge, UK), MCF-7 and H-2b EL4 cells were maintained in 
Dulbecco's Modified Eagle's medium (DMEM; Sigma-Aldrich, UK) supplemented with 10% 
fetal bovine serum (FBS) (Gibco, Thermo Fisher Scientific), 100 U/ml penicillin and 100 
µg/ml streptomycin (Gibco, Thermo Fisher Scientific) at 37°C with 5% CO2. To induce 
expression of endogenously-expressed TAPBPR and up-regulate other components of the 
MHC class I antigen processing and presentation pathway, HeLaM and MCF-7 cells were 
treated with 200 U/ml IFNγ (Peprotech, UK) for 48–72 h where indicated. 
 
Lentiviral transduction and transfections 
Lentivirus was produced by transfecting HEK-293T cells with lentiviral vectors along with 
the packaging vector pCMVΔR8.91 and the envelope vector pMD.G using Fugene (Promega, 
UK). Viral supernatant was collected at 48 h and used to transduce different cell lines, as 
followed: TAPBPRWT, TAPBPRTN5, TAPBPRPM, TAPBPRER, tapasinWT and tapasinPM were 
reconstituted in a TAPBPR-deficient HeLaM cell line (HeLaM-TAPBPRKO) (10); HLA-
A*02:01 and HLA-A*68:02 were reconstituted in a HeLaM cell line deficient of the HLA-
A,-B and -C (HeLaM-HLA-ABCKO)(Neerincx & Boyle, manuscript in revision at Molecular 
Immunology). HeLa HLA-A2 pp65 cells were generated by transducing HeLaM cells first 
with HLA-A2-pHRSINcPPT-SGW, followed by pp65-pHRSIN-C56W-UbEM.  
 
Antibodies 
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TAPBPR was detected using either PeTe4, a mouse monoclonal antibody (mAb) specific for 
the native conformation of TAPBPR, raised against amino acids 22–406 of human TAPBPR 
(5) that does not cross-react with tapasin (15), or ab57411, a mouse mAb raised against 
amino acids 23–122 of TAPBPR that is reactive to denatured TAPBPR (Abcam, UK). 
Tapasin was detected using Pasta-1 (28)(A kind gift from Peter Cresswell, Yale). UGT1 was 
detected using the rabbit mAb ab124879 (Abcam). MHC class I heavy chains were detected 
using mAb HC10 (29).  OVA257-264 [SIINFEKL] peptide on H-2Kb was detected using the 
mAb 25D-1.16 (Thermofisher). The Epstein-Barr Virus derived peptide Latent Membrane 
Protein 1125–133 [YLLEMLWRL] in association with HLA-A*02:01 was detected using the 
TCR-like mAb L1 (17) (a king gift from Paul MacAry, University of Singapore). A mouse 
IgG2a isotype control was also used as a control (Sigma-Aldrich).  
 
MHC class I-binding peptides 
The following MHC-class I specific peptides were used: HLA-A*68:02-binding peptide 
ETVSEQSNV, its derivative EGVSEQSNG, obtained by replacing its anchor residues 
(amino acids on positions 2 and 9) with glycine, as well as their fluorescently-labelled 
versions ETVSK*QSNV and EGVSK*QSNG, respectively (K* represents a lysine labelled 
with 5-carboxytetramethylrhodaime [TAMRA]); HLA-A*02:01 binding peptides 
NLVPMVATV, YLLEMLWRL, CLGGLLTMV, YVVPFVAKV, IMDQVPFSV, 
LLGRNSFEV, ELAGIGILTV and RLLQETELV, together with their fluorescently-labelled 
variants NLVPK*VATV, YLLEK*LWRL, CLGGK*LTMV, YVVPFVAK*V, 
IMDQK*PFSV, LLGRK*SFEV, ELAGK*GILTV and RLLQK*TELV, respectively; HLA-
B*27:05 specific peptide SRYWAIRTR and its fluorescently-labelled variant 
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SRYWK*IRTR; H-2Kb specific peptide SIINFEKL and its fluorescently-labelled variant 
SIINFEK*L. All peptides were purchased from Peptide Synthetics, UK. 
 
Expression and purification of TAPBPR protein 
Secreted forms of either TAPBPRWT or TAPBPRTN5 were expressed in HEK 293T cells, 
using the PiggyBac expression system. The C-terminally His-tagged ectodomain of either 
protein was cloned into the PB-T-PAF vector. 293T cells were co-transfected in 6-well plates 
with 0.9 µg PB vector and 0.15 µg of both PB-RN and PBase (at a ratio of 6:1:1). 48 h after 
transfection, cells were transferred for at least 5 days into selection media (DMEM 
supplemented with 10% FBS, 1% pen/strep, 3 µg/mL puromycin (Invivogen, San Diego, CA) 
and 700 µg/mL geneticin (Thermo Fisher Scientific, UK). To induce protein expression, cells 
were harvested and transferred into DMEM supplemented with 5% FBS, 1% pen/strep and 2 
µg/mL doxycycline (Sigma-Aldrich, UK). After 7 days, the media was collected and 
TAPBPR was purified using Ni-NTA affinity chromatography. For purity assessment, elution 
fractions were analysed by SDS-PAGE, followed by Coomassie staining.     
 
Flow cytometry 
Following trypsinisation, cells were washed in 1% bovine serum albumin (BSA), dissolved in 
1x phosphate-buffered saline (PBS) at 4°C, and then stained for 30 min at 4°C in 1% BSA 
containing one of the following antibodies: PeTe4, Pasta-1, TCR-like mAb L1, 25-D1.16 or 
with an isotype control antibody. After washing the cells to remove excess unbound antibody, 
the primary antibodies bound to the cells were detected by incubation at 4°C for 25 min with 
either goat anti-mouse Alexa-Fluor 647 IgG (Invitrogen Molecular Probes, Thermo Fisher 
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Scientific). After subsequent three rounds of washing, the fluorescence levels were detected 
using a BD FACScan analyser with Cytek modifications and analysed using FlowJo (FlowJo, 
LLC, Ashland, OR).  
 
Immunoprecipitation, gel electrophoresis and western blotting 
Cells were harvested then washed in PBS. For immunoprecipitation of the TAPBPR fraction 
present at the plasma membrane, cells were incubated with 2 µg PeTe4 antibody in 1% BSA 
in 1x PBS for 1 h with rotation at 4°C. Excess antibody was removed by washing the cells 5 
times in 1x PBS at 4°C. Cells were then lysed in 1% triton X-100 (VWR, Radnor, PN), Tris-
buffered saline (TBS) (20 mM Tris-HCl, 150 mM NaCl, 2.5 mM CaCl2), supplemented with 
10 mM NEM, 1 mM phenylmethylsulfonyl fluoride (PMSF) (Sigma-Aldrich), and protease 
inhibitor cocktail (Roche, UK) for 30 min at 4°C. Nuclei and cell debris were pelleted by 
centrifugation at 13,000 × g for 15 min and supernatants were collected. The TAPBPR 
fraction originally present the plasma membrane, bound to the PeTe4 antibody, was then 
precipitated using protein A sepharose beads alone (GE Healthcare) for 2 h at 4°C with 
rotation. Following the immunoprecipitation of the plasma membrane TAPBPR fraction, the 
flow through was collected and subjected to a subsequent round of immunoprecipitation, this 
time using protein A sepharose beads conjugated to PeTe4 antibody, in order to pull down the 
intracellular TAPBPR fraction. Following immunoprecipitation, beads were washed 
thoroughly in 0.1% detergent-TBS to remove unbound protein. For separation by gel 
electrophoresis, the samples were heated at 94°C for 10 min in sample buffer (125 mM Tris-
HCl pH 6.8, 4% SDS, 20% glycerol, 0.04% bromophenol blue), supplemented with 100 mM 
β-mercaptoethanol. In order to detect the samples by western blotting, proteins were 
transferred onto an Immobilon transfer membrane (Merck Millipore). Membranes were 
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blocked using 5% (w/v) dried milk and 0.05% (v/v) Tween 20 in PBS for 30 min and 
subsequently incubated with the indicated primary antibody for 1–16 h. After washing, 
membranes were incubated with species-specific HRP-conjugated secondary antibodies, 
washed and detected by enhanced chemiluminescence using Western Lightning (Perkin 
Elmer, UK) and Super RX film (Fujifilm, UK). Films were scanned on a CanoScan8800F 
using MX Navigator Software (Canon, UK).  
For pulldown experiments using soluble TAPBPR proteins, protein A sepharose precleared 
lysates from IFNγ-stimulated HeLaM-TAPBPRKO cells were incubated with 5 µg of the 
soluble TAPBPR variant for 90 min at 4°C. Immunoprecipitation of soluble TAPBPR was 
performed using PeTe4 as above.  Soluble TAPBPR was detected on western blots with the 
anti-poly His primary antibody. 
 
 
Peptide binding 
Target cell lines were seeded at 25,000-30,000 cells/well in 12-well plates and stimulated 
with IFNγ. Following the stimulation period, the cells were washed 3 times with 1x PBS and 
incubated with 300 μL pre-warmed opti-MEM (Thermo Fisher Scientific, UK). In case the 
peptide binding was done in the presence of recombinant TAPBPR, the cells were then 
treated with or without recombinant TAPBPR (100 nM for HLA-A*68:02 or 1 µM for HLA-
A*02:01 and H-2Kb). After 15 min, the desired TAMRA-labelled peptide was added to the 
cells and incubated at 37°C (15 min for HLA-A*68:02, 60 min for HLA-A*02:01 or 30 min 
for H-2Kb). In case the peptide binding was facilitated by over-expressed TAPBPR, the 
labelled peptide was directly added to the cells, without using recombinant TAPBPR. 
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Following the peptide treatment, the cells were washed three times in 1x PBS and harvested. 
The level of bound peptide/cell was determined by flow cytometry, using the YelFL1 channel 
(Cytek).  
 
Peptide exchange 
HeLaM-TAPBPRKO cells, reconstituted with TAPBPR were seeded at 25,000 cells/well and 
stimulated with IFNγ. The cells were then washed and treated with 10 nM TAMRA-labelled 
peptide of interest diluted in opti-MEM for 15 min at 37°C, as described above. Following 
the binding step, the peptide-containing media was removed, the cells were washed and then 
treated with media alone or with different concentrations of non-labelled peptide for another 
15 min at 37°C. The cells were then washed and harvested and the level of bound peptide per 
cell was determined by flow cytometry, using the YelFL1 channel (Cytek). 
 
FluoroSpot T cell assay 
Expansion of HCMV specific CD8+ T cells 
CD8+ T cells were isolated from PBMC using MACS anti-CD8 direct beads (Miltenyi 
Biotec, Bisley, United Kingdom) magnetic separation and then resuspended in supplemented 
RPMI + 10% Fetal Bovine Serum (FBS) (Invitrogen) + 10% heat inactivated autologous 
donor serum. Cells were stimulated with peptide pulsed irradiated autologous PBMC in the 
presence of 2.5 IU/ml human recombinant IL-2 (National Institute for Biological Standards 
and Control, Potters Bar, United Kingdom) in round bottom 96 well plates at 37ºC +5% 
CO2 for 10 – 14 days, fresh media was replenished every five days. Specificity of expanded 
CD8+ T cell cultures were tested for specificity using IFNγ FLUOROSPOT assays 
27 
 
stimulated with HeLa HLA-A2 pp65 cells. Individual HLA restricted peptides from HCMV 
pp65 used in this study were HLA-A2 NLVPMVATV (pp65 495 -504aa). 
Ethical approval was obtained from the Addenbrookes National Health Service Hospital 
Trust institutional review board (Cambridge Research Ethics Committee) for this study. 
Informed written consent was obtained from all recipients in accordance with the Declaration 
of Helsinki (LREC 97/092). 
 Experimental set up 
Target cells (MCF-7 or HeLaM-HLA-ABCKO reconstituted with HLA-A*02:01 heavy chain) 
were seeded at 80,000 cells/well of a 6-well plate and stimulated with IFNγ for 72 h. Cells 
were then washed 3 times with 1x PBS and incubated with 600 μL pre-warmed opti-MEM, 
containing either soluble TAPBPRWT, TAPBPRTN5, or without TAPBPR. After 15 min, 100 
pM NLVPMVATV peptide was added to the desired samples and incubated for another 60 
min. Following peptide treatment, cells were washed 3 times in 1x PBS and harvested. Each 
sample was then washed again twice in 1x PBS and resuspended in X-VIVO 15 media 
(Lonza, Slough, UK) at 1x106 cells/mL. Target cells were then irradiated for 20 min, in order 
to cease proliferation throughout the experiment. Triplicate wells of NLVPMVATV specific 
CD8+ T cells in X-VIVO 15 media were incubated in coated Fluorospot plates (Human IFNγ 
FLUOROSPOT (Mabtech AB, Nacka Strand, Sweden)), at 8,000 cells/well, with target cells, 
at 50,000 cells/well, at 37°C in a humidified CO2  atmosphere for 20 hours. The cells and 
medium were decanted from the plate and the assay developed following the manufacturer's 
instructions.  Developed plates were read using an AID iSpot reader (Autoimmun 
Diagnostika (AID) GmbH, Strassberg, Germany) and counted using EliSpot v7 software 
(Autoimmun Diagnostika). 
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Mice 
OT-I RAG2-/- mice were a generous gift from Suzanne Turner (Dept. of Pathology, 
University of Cambridge) and were bred and housed in accordance with UK Home Office 
regulations. 
 
Cytotoxicity assay 
To generate OT-I cytotoxic T lymphocytes (CTL), spleens were extracted from OT-I RAG2-/- 
mice and single cell suspensions of splenocytes were obtained using a 70 μm cell strainer 
(Greiner Bio-one).  Splenocytes were stimulated with 10 nM OVA257-264 (SIINFEKL) peptide 
(Peprotech, UK). After 3 days of culture cells were washed, seeded into fresh T cell media 
daily and used 3-4 days later.  T cells were cultured in RPMI 1640 medium with L-glutamine 
(Gibco, Thermo Fisher Scientific), 10% heat–inactivated FCS (Biosera), 50 μM of β-
mercaptoethanol, 1 mM sodium pyruvate (Gibco, Thermo Fisher Scientific), 10 mM Hepes 
(Sigma-Aldrich), 50 IU/ml recombinant murine IL-2 (Peprotech, UK) and 50 U/ml penicillin 
and streptomycin (Gibco, Thermo Fisher Scientific) (T cell media). 
The CytoTox96 Non-Radioactive Cytotoxicity Assay (Promega) was used to measure EL4 
target cell death. Target H-2b EL4 cells were washed the day prior to the experiment and 
resuspended in fresh DMEM at 3x105 - 4x105 cells/ml. The following morning, the EL4 cells 
were washed once and resuspended in warm opti-MEM at 5x105 cells/ml. The cells were 
treated initially with 1 μM soluble TAPBPR alone or with carrier alone for 10 min, after 
which either 1 nM OVA257-264 [SIINFEKL] peptide or carrier alone was added to the cells for 
another 30 min. Cells were then washed 1x in Optimem and 2x in killing assay media (RPMI 
medium minus phenol red, 2% FCS), and resuspended in killing assay media at 1x105 
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cells/ml in a round-bottom 96-well plate.  Effector OT-I CTLs were washed in killing assay 
media once and then added to the plate at titrated effector to target cell (E:T) ratios. Plates 
were incubated at 37C and after 6-7 hours EL4 killing was assessed by release of lactate 
dehydrogenase in the supernatant. 
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Figure legends 
Fig. 1 - Surface expressed TAPBPR enhances exogenous peptide association onto MHC 
I  
Surface expression of (a,d) TAPBPR, detected using the mAb PeTe-4 or (g) tapasin, detected 
using Pasta1 on IFNγ treated (a) HeLaM cells and HeLaM-TAPBPRKO -/+ TAPBPRWT 
transduction, (d) HeLaM-TAPBPRKO -/+  TAPBPRPM or TAPBPRER transduction or (g) 
HeLaM-TAPBPRKO -/+ tapasinWT or tapasinPM transduction. Staining with an isotype control 
(solid black line) is included in a. Note: HeLaM-TAPBPRKOTAPBPRPM cells with low 
transduction levels were selected to generate cells with similar surface expression as 
TAPBPRWT.  (b,e,h) Histograms show the typical peptide binding observed when the cells 
were incubated with the HLA-A*68:02 specific fluorescent peptide ETVSK*QSNV at 10 nM 
for 15 min at 37oC. (c&i) Bar chart summarising the level of exogenous fluorescent peptide 
binding when cells were incubated with 10 nM EGVSK*QSNG, ETVSK*QSNV, or 
YVVPFVAK*V for 15 min at 37oC. Bars show mean fluorescence intensity (MFI) -/+ SD 
from three independent experiments.  n/s not significant, **P≤0.01, ***P ≤ 0.001, 
****P≤0.0001 using unpaired two-tailed t-test. (f) Immunoprecipitation of the cell surface 
pool of TAPBPR, by staining intact cells with PeTe-4 before lysis and addition of Protein-A 
sepharose, and the remaining intracellular TAPBPR pool from cells post-surface TAPBPR 
preclear, followed by Western blotting for TAPBPR, MHC I (using HC10) or UGT1, on 
immunoprecipitates and lysates as indicated. Data shown is representative of three 
independent experiments. For comparison, a classical co-immunoprecipitation from these 
cells is also provided (Fig. S1d).  
 
Fig. 2 - Surface TAPBPR functions as a MHC I peptide exchange catalyst 
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(a) Time course and (b) dose response curves showing the level of exogenous 
ETVSK*QSNV binding to IFNγ treated HeLaM, HeLaM-TAPBPRKO -/+ TAPBPRWT, and to 
HeLaM-HLA-ABCKO cells treated with (a) 10 nM ETVSK*QSNV from 0-180 min at 37oC 
or (b) increasing concentration of ETVSK*QSNV for 15 min. Line graphs show MFI -/+ SD 
from three independent experiments. Histograms displaying the typical fluorescent peptide 
binding observed on HeLaMKO-TAPBPRWT expressing cells for both the time course and 
dose response experiment are provided in Fig. S2c and Fig. S2d, respectively.  Note: in (b) 
ETVSK*QSNV binding using 1nM-1 µM peptide was dependent on MHC I, given that no 
exogenous peptide association was observed on HeLaM-HLA-ABCKO cells at these 
concentrations. (c) Schematic representation of experimental workflow used to measure 
peptide exchange by plasma membrane bound TAPBPR. (d-g) IFNγ treated 
HeLaKOTAPBPRWT cells were incubated with 10 nM (d,f) YVVPKVAK*V or (e,g) 
ETVSK*QSNV for 15 min at 37oC, then washed to remove unbound peptide. Dissociation of 
the fluorescent peptides was subsequently monitored in the absence or presence of increasing 
concentrations of the unlabelled competitor peptides YVVPFVAKV (YVV), ETVSEQSNV 
(ETV) or EGVSEQSNG (ETVΔ2/9) for 15 min at 37oC. (d,e) Histograms show the typical 
dissociation of fluorescent peptide observed following incubation with 100 nM competitor 
peptide. (f.g) Line graphs show the percentage of fluorescent peptide remaining -/+ SD 
following treatment with increasing concentrations of unlabelled peptide from (f) four and (g) 
three independent experiments. 
 
Fig. 3 - Soluble TAPBPR enhances exogenous peptide association onto surface MHC I 
(a) IFNγ treated HeLaM cells were incubated -/+ 100 nM soluble TAPBPRWT or TAPBPRTN5 
for 15 min at 37oC, followed by detection of surface bound TAPBPR using PeTe-4. Soluble 
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TAPBPRWT binding to HeLaM-HLA-ABCKO cells (-) is included as a control. (b) TAPBPR 
pulldowns on lysates from IFNγ treated HeLaM-TAPBPRKO cells incubated -/+ soluble 
TAPBPRTN5 or TAPBPRWT demonstrates TAPBPRWT binds to MHC I. Data is representative 
of three independent experiments. (c) Schematic representation of experimental workflow 
used to measure peptide exchange by soluble TAPBPR.  (d&e) IFNγ treated HeLaM cells 
were -/+ 100 nM soluble TAPBPRWT or TAPBPRTN5 for 15 min at 37oC, followed by 
incubation -/+ 10 nM ETVSK*QSNV (ETV*), YVVPFVAK*V (YVV*) or EGVSK*QSNG 
(ETVΔ2/9) for 15 min at 37oC. In (d) histograms show the typical binding observed for 
ETVSK*QSNV and YVVPFVAK*V and (e) shows the MFI of fluorescent peptide binding -
/+ SD from three independent experiments. (f) Dose response curves -/+ SD from three 
independent experiments of ETVSK*QSNV binding to IFNγ treated HeLaM and HeLaM-
HLA-ABCKO cells treated -/+ 100 nM TAPBPR with increasing concentrations of peptide 15 
min at 37oC. (g) Bar graph showing the MFI of fluorescent peptide binding to IFNγ treated 
HeLaM-HLA-ABCKO cells reconstituted with HLA-A*02:01 -/+ SD from two independent 
experiments with duplicates. Cells were incubated in the absence or presence of 1 µM soluble 
TAPBPRWT or TAPBPRTN5 for 15 min, followed by incubation with 10 nM NLVPK*VATV 
(NLV*), YVVPFVAK*V (YVV*), YLLEK*LWRL (YLL*), CLGGK*LTMV (CLG*) 
ETVSK*QSNV (ETV*) or SRYWK*IRTR (SRY*) for 60 min. ***P ≤ 0.001, 
****P≤0.0001, n/s not significant, using unpaired two-tailed t-test.  
 
Fig. 4 - Antigenic peptides loaded onto MHC I via TAPBPR are available to the T cell 
receptor 
MCF-7 cells were treated -/+ 1 µM soluble TAPBPRWT or TAPBPRTN5 for 15 min at 37oC 
followed by 60 min incubation -/+ 10 nM (a) IMDQK*PFSV, ELAGK*GILTV, 
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LLGRK*SFEV, or RLLQK*TELV, (b) NLVPK*VATV or YLLEK*LWRL or (c&d) 
YLLEMLWRL (YLL) followed by staining with the TCR-like mAb L1 specific for 
YLLEMLWRL/HLA-A2 complexes.  (d) The MFI of L1 binding to MCF-7 cells -/+ SD 
from three independent experiments. (e) Bar graphs show T cell activity measured by IFN-γ 
secretion in fluorospot assays of a HLA-A2 restricted NLVPMVATV specific CD8+ T cell 
line when incubated with MCF-7 target cells as treated in b with the exception that non-
fluorescent NLVPMVATV peptide at 100 pM was used. Results are from triplicate wells 
representative of two independent experiments. Error bars -/+ SD. Note: In a, b, & e IFNγ 
treated cells were used. Equivalent experiments of b-e were performed using HeLaM-HLA-
ABCKO expressing HLA-A*02:01 and can be found in Fig. S7. *P ≤0.05, ***P ≤ 0.001, 
****P≤0.0001 using unpaired two-tailed t-test. 
 
Fig. 5 - Soluble TAPBPR enhances T cell killing of tumour cells   
EL4 cells were incubated -/+ 1µM soluble TAPBPRWT or TAPBPRTN5 for 15 min at 37oC, 
followed by (a) detection of surface bound TAPBPR using PeTe-4, (b) incubation -/+ 1 nM 
SIINFEK*L for 30 min at 37oC or (c) incubation -/+ 1 nM non-labelled SIINFEKL peptide 
for 30 min, followed by staining with the 25-D1.16 mAb (recognises SIINFEKL/H-2Kb 
complexes).  Histograms are representative of three independent experiments. (d) Bar graphs 
show the MFI of 25-D1.16 -/+ SD from three independent experiments. (e) OT1 killing of 
EL4 cells treated -/+ 1µM soluble TAPBPRWT or TAPBPRTN5, followed by incubation with 1 
nM SIINFEKL peptide. Error bars -/+ s.e.m from triplicate wells. Data is representative of 
three independent experiments.  Note: surface expressed H-2Kb are relatively more peptide 
receptive compared to human MHC I molecules. At 10 nM SIINFEKL, some exogenous 
peptide binding was observed in the absence of soluble TAPBPRWT. As OT1 T cells are 
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highly efficient cytotoxic cells, killing 80-100% of targets after 1-4 hours, we decreased the 
concentration of SIINFEKL used in these experiments to 1 nM in order to differentiate 
between TAPBPR-mediated and background peptide binding, otherwise we would not 
observe an additive effect of soluble TAPBPR on target cell killing. 
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